Cargando…

Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer

AIMS: To assess the diagnostic value of CEA and CYFRA 21-1 (cytokeratin 19 fragments) in serum and pleural fluid in non small cell lung cancer with malignant pleural effusion (MPE). SETTINGS AND DESIGN: Two subsets of patients were recruited with lymphocytic exudative effusion, one subset constitute...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Sushil Kumar, Bhat, Sanjay, Chandel, Vikas, Sharma, Mayank, Sharma, Pulkit, Gupta, Sakul, Sharma, Sashank, Bhat, Aijaz Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736054/
https://www.ncbi.nlm.nih.gov/pubmed/26900349
http://dx.doi.org/10.4103/1477-3163.170662
_version_ 1782413199731064832
author Sharma, Sushil Kumar
Bhat, Sanjay
Chandel, Vikas
Sharma, Mayank
Sharma, Pulkit
Gupta, Sakul
Sharma, Sashank
Bhat, Aijaz Ahmed
author_facet Sharma, Sushil Kumar
Bhat, Sanjay
Chandel, Vikas
Sharma, Mayank
Sharma, Pulkit
Gupta, Sakul
Sharma, Sashank
Bhat, Aijaz Ahmed
author_sort Sharma, Sushil Kumar
collection PubMed
description AIMS: To assess the diagnostic value of CEA and CYFRA 21-1 (cytokeratin 19 fragments) in serum and pleural fluid in non small cell lung cancer with malignant pleural effusion (MPE). SETTINGS AND DESIGN: Two subsets of patients were recruited with lymphocytic exudative effusion, one subset constituted diagnosed patients of NSCLC with malignant pleural effusion and the other subset of constituted with Tubercular pleural effusion. MATERIALS AND METHODS: CYFRA 21-1 and CEA levels were measured using Electrochemilumiscence Immunoassay (ECLIA). The test principle used the Sandwich method. For both the tests, results are determined via a calibration curve which is instrument specifically generated by 2 - point calibration and a master curve provided via reagent barcode. STATISTICAL ANALYSIS USED: All data are expressed as means ± SD and percentage. All the parametric variables were analysed by student-t test where as non parametric variables were compared by Mann-Whitney U-test Statistical significance was accepted for P values < 0.05. Software used were SPSS 11.5, and MS excel 2007. In order to compare the performance of the tumor markers, receiver operating characteristic (ROC) curves were constructed and compared with area under the curve (AUC). The threshold for each marker was selected based on the best diagnostic efficacy having achieved equilibrium between sensitivity and specificity. RESULTS: In cases serum CYFRA21-1 levels had mean value of 34.1 ± 29.9 with a range of 1.6-128.3 where as in controls serum CYFRA21-1 levels had mean value of 1.9 ± 1.0 with a range of 0.5–4.7. In cases serum CEA levels had mean value of 24.9 ± 47.3 with a range of 1.0, 267.9 where as in controls serum CEA levels had mean value of 1.9 ± 1.4 with a range of 0.2-6.8. The difference in the means of serum CYFRA 21-l (P = 0.000) and CEA (P = 0.046) were statistically significant. In cases pleural fluid CYFRA21-1 levels had mean value of 160.1 ± 177.1 with a range of 5.4–517.2 where as in controls pleural fluid CYFRA21-1 levels had mean value of 15.9 ± 5.7 with a range of 7.2-29.6. In cases CEA pleural fluid levels had mean value of 89.8 ± 207.4 with a range of 1.0–861.2 where as in controls CEA levels had mean value of 2.5 ± 2.3 with a range of 1–8.9. The difference in the means of CYERA 21-1 (P = 0.001) between cases and controls is statistically significant. CONCLUSIONS: CYFRA21-1 (serum - pleural fluid) is a sensitive marker for NSCLC with sensitivity of 96.7%, highest of any combination [Serum (CYFRA 21-1 - CEA). CEA (Serum + Pleural Fluid), Pleural Fluid (CYFRA 21-1 + CEA)] and specificity of 77.8%. Levels of CYFRA21-l (serum + pleural fluid) are increased in malignant pleural effusion, so it is better to be used in suspicious malignant pleural effusion showing negative cytology, particularly in the absence of a visible tumor and or unsuitability for invasive procedure.
format Online
Article
Text
id pubmed-4736054
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47360542016-02-19 Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer Sharma, Sushil Kumar Bhat, Sanjay Chandel, Vikas Sharma, Mayank Sharma, Pulkit Gupta, Sakul Sharma, Sashank Bhat, Aijaz Ahmed J Carcinog Original Article AIMS: To assess the diagnostic value of CEA and CYFRA 21-1 (cytokeratin 19 fragments) in serum and pleural fluid in non small cell lung cancer with malignant pleural effusion (MPE). SETTINGS AND DESIGN: Two subsets of patients were recruited with lymphocytic exudative effusion, one subset constituted diagnosed patients of NSCLC with malignant pleural effusion and the other subset of constituted with Tubercular pleural effusion. MATERIALS AND METHODS: CYFRA 21-1 and CEA levels were measured using Electrochemilumiscence Immunoassay (ECLIA). The test principle used the Sandwich method. For both the tests, results are determined via a calibration curve which is instrument specifically generated by 2 - point calibration and a master curve provided via reagent barcode. STATISTICAL ANALYSIS USED: All data are expressed as means ± SD and percentage. All the parametric variables were analysed by student-t test where as non parametric variables were compared by Mann-Whitney U-test Statistical significance was accepted for P values < 0.05. Software used were SPSS 11.5, and MS excel 2007. In order to compare the performance of the tumor markers, receiver operating characteristic (ROC) curves were constructed and compared with area under the curve (AUC). The threshold for each marker was selected based on the best diagnostic efficacy having achieved equilibrium between sensitivity and specificity. RESULTS: In cases serum CYFRA21-1 levels had mean value of 34.1 ± 29.9 with a range of 1.6-128.3 where as in controls serum CYFRA21-1 levels had mean value of 1.9 ± 1.0 with a range of 0.5–4.7. In cases serum CEA levels had mean value of 24.9 ± 47.3 with a range of 1.0, 267.9 where as in controls serum CEA levels had mean value of 1.9 ± 1.4 with a range of 0.2-6.8. The difference in the means of serum CYFRA 21-l (P = 0.000) and CEA (P = 0.046) were statistically significant. In cases pleural fluid CYFRA21-1 levels had mean value of 160.1 ± 177.1 with a range of 5.4–517.2 where as in controls pleural fluid CYFRA21-1 levels had mean value of 15.9 ± 5.7 with a range of 7.2-29.6. In cases CEA pleural fluid levels had mean value of 89.8 ± 207.4 with a range of 1.0–861.2 where as in controls CEA levels had mean value of 2.5 ± 2.3 with a range of 1–8.9. The difference in the means of CYERA 21-1 (P = 0.001) between cases and controls is statistically significant. CONCLUSIONS: CYFRA21-1 (serum - pleural fluid) is a sensitive marker for NSCLC with sensitivity of 96.7%, highest of any combination [Serum (CYFRA 21-1 - CEA). CEA (Serum + Pleural Fluid), Pleural Fluid (CYFRA 21-1 + CEA)] and specificity of 77.8%. Levels of CYFRA21-l (serum + pleural fluid) are increased in malignant pleural effusion, so it is better to be used in suspicious malignant pleural effusion showing negative cytology, particularly in the absence of a visible tumor and or unsuitability for invasive procedure. Medknow Publications & Media Pvt Ltd 2015-11-27 /pmc/articles/PMC4736054/ /pubmed/26900349 http://dx.doi.org/10.4103/1477-3163.170662 Text en Copyright: © 2015 Sharma http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Sharma, Sushil Kumar
Bhat, Sanjay
Chandel, Vikas
Sharma, Mayank
Sharma, Pulkit
Gupta, Sakul
Sharma, Sashank
Bhat, Aijaz Ahmed
Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer
title Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer
title_full Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer
title_fullStr Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer
title_full_unstemmed Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer
title_short Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer
title_sort diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736054/
https://www.ncbi.nlm.nih.gov/pubmed/26900349
http://dx.doi.org/10.4103/1477-3163.170662
work_keys_str_mv AT sharmasushilkumar diagnosticutilityofserumandpleuralfluidcarcinoembryonicantigenandcytokeratin19fragmentsinpatientswitheffusionfromnonsmallcelllungcancer
AT bhatsanjay diagnosticutilityofserumandpleuralfluidcarcinoembryonicantigenandcytokeratin19fragmentsinpatientswitheffusionfromnonsmallcelllungcancer
AT chandelvikas diagnosticutilityofserumandpleuralfluidcarcinoembryonicantigenandcytokeratin19fragmentsinpatientswitheffusionfromnonsmallcelllungcancer
AT sharmamayank diagnosticutilityofserumandpleuralfluidcarcinoembryonicantigenandcytokeratin19fragmentsinpatientswitheffusionfromnonsmallcelllungcancer
AT sharmapulkit diagnosticutilityofserumandpleuralfluidcarcinoembryonicantigenandcytokeratin19fragmentsinpatientswitheffusionfromnonsmallcelllungcancer
AT guptasakul diagnosticutilityofserumandpleuralfluidcarcinoembryonicantigenandcytokeratin19fragmentsinpatientswitheffusionfromnonsmallcelllungcancer
AT sharmasashank diagnosticutilityofserumandpleuralfluidcarcinoembryonicantigenandcytokeratin19fragmentsinpatientswitheffusionfromnonsmallcelllungcancer
AT bhataijazahmed diagnosticutilityofserumandpleuralfluidcarcinoembryonicantigenandcytokeratin19fragmentsinpatientswitheffusionfromnonsmallcelllungcancer